MOZ-IN-3

Confirm delete?

MOZ-IN-3

Zoom

Cat No: 27402

Biochemicals - Small Molecule Inhibitors

MOZ-IN-3 is an inhibitor of lysine acetyltransferase 6A (KAT6A/MOZ) and KAT6B/MORF (IC50s = 8 and 28 nM, respectively).{51034} It is selective for KAT6A and KAT6B over KAT5 and KAT7 (IC50s = 224 and 342 nM, respectively). MOZ-IN-3 induces cell cycle a...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

4-fluoro-5-methyl-[1,1'-biphenyl]-3-carboxylic acid, 2-(phenylsulfonyl)hydrazide

Correlated keywords:

MOZIN3 KAT-6A-6B-5-7 EMRK-1184 H-3 H3k-14Ac-9Ac acetyl transferase H3 K14Ac K9Ac Ezh 2 E2 F2 WM8014

Product Overview:
MOZ-IN-3 is an inhibitor of lysine acetyltransferase 6A (KAT6A/MOZ) and KAT6B/MORF (IC50s = 8 and 28 nM, respectively).{51034} It is selective for KAT6A and KAT6B over KAT5 and KAT7 (IC50s = 224 and 342 nM, respectively). MOZ-IN-3 induces cell cycle arrest in and inhibits proliferation of mouse embryonic fibroblasts (IC50 = 2.4 µM) and inhibits proliferation of EMRK1184 lymphoma cells (IC50 = 2.3 µM). It induces genetic and morphological changes associated with cellular senescence without inducing DNA damage, apoptosis, or necrosis. MOZ-IN-3 (10 µM) decreases global levels of acetylated histone H3 lysine 14 (H3K14Ac) by 49% and reduces H3K9Ac levels at the transcription start sites of Ezh2, Melk, and E2f2.

Size	500 µg
Shipping	dry ice
CAS Number	2055397-18-5
Molecular Formula	C₂₀H₁₇FN₂O₃S
SMILES	CC1=C(F)C(C(NNS(C2=CC=CC=C2)(=O)=O)=O)=CC(C3=CC=CC=C3)=C1
Molecular Weight	384,4
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2903.99
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.